Increased values of alpha-fetoprotein can predict tumor recurrence following resection, the level of response to loco-regional therapy, the drop-out risk among patients awaiting liver transplantation (LT), as well as survival and tumor recurrence following LT, and survival in advanced HCC. This evidence concerns the gene AFP and hepatocellular carcinoma.